Haystack Sciences

2:30 PM - 2:45 PM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
Exponential reductions in the cost of DNA sequencing, combined with the advanced computational methods of machine learning & artificial intelligence (ML/AI), will inevitably disrupt the costly & time-consuming process of finding cures for difficult-to-treat diseases.Haystack is at the forefront.

Haystack’s proprietary methods for synthesizing, breeding, and analyzing large, diverse combinatorial chemical libraries encoded by unique DNA sequences (DNA-Encoded Libraries, or DELs) establishes a revolutionary, data-intensive platform for discovering new cures for difficult-to-treat disorders.

Most notably, Haystack has developed nDexer(tm), a platform for precise selections from DELs, and has applied it to a number of different targets and target classes, allowing the company to produce very large, high-quality data sets for subsequent computational analysis.
Company Type:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2016
Main Therapeutic Focus:
Lead Product in Development:
nDexer(tm)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided